Mbio
-
Much remains unknown about how the intestinal microbiome interfaces with the protective intestinal mucus layer. Bifidobacterium species colonize the intestinal mucus layer and can modulate mucus production by goblet cells. However, select Bifidobacterium strains can also degrade protective glycans on mucin proteins. ⋯ Using a combination of gnotobiotic mice and mucus-secreting cell lines, we have identified a human-derived microbe, Bifidobacterium dentium, which adheres to intestinal mucus and secretes metabolites that upregulate the major mucin MUC2 and modulate goblet cell function. Unlike other Bifidobacterium species, B. dentium does not extensively degrade mucin glycans and cannot grow on mucin alone. This work points to the potential of using B. dentium and similar mucin-friendly microbes as therapeutic agents for intestinal disorders with disruptions in the mucus barrier.
-
Comparative Study
Blacklists and Whitelists To Tackle Predatory Publishing: a Cross-Sectional Comparison and Thematic Analysis.
We aimed to develop an in-depth understanding of quality criteria for scholarly journals by analyzing journals and publishers indexed in blacklists of predatory journals and whitelists of legitimate journals and the lists' inclusion criteria. To quantify content overlaps between blacklists and whitelists, we employed the Jaro-Winkler string metric. To identify topics addressed by the lists' inclusion criteria and to derive their concepts, we conducted qualitative coding. ⋯ Blacklists of predatory journals and whitelists of legitimate journals have been developed but not comprehensively examined. By systematically analyzing these lists, this study provides insights into their utility and delineates the different notions of quality and legitimacy in scholarly publishing used. This study contributes to a better understanding of the relevant concepts and provides a starting point for the development of a robust definition of predatory journals.
-
Secondary bacterial lung infection by Streptococcus pneumoniae (S. pneumoniae) poses a serious health concern, especially in developing countries. We posit that the emergence of multiantibiotic-resistant strains will jeopardize current treatments in these regions. Deaths arising from secondary infections are more often associated with acute lung injury, a common consequence of hypercytokinemia, than with the infection per se Given that secondary bacterial pneumonia often has a poor prognosis, newer approaches to improve treatment outcomes are urgently needed to reduce the high levels of morbidity and mortality. ⋯ The immunoneutralization of host protein cANGPTL4 reduced the severity of pulmonary edema and damage. We show that host-directed therapeutic strategies as well as neutralizing antibodies against pathogen virulence factors are viable adjuncts to standard antimicrobial treatments such as antibiotics. In view of their different modes of action compared to antibiotics, concurrent immunotherapies using antibodies are potentially efficacious against secondary pneumococcal pneumonia caused by antibiotic-resistant pathogens.